Skip to Content

Nanosonics Ltd

NAN: XASX (AUS)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
A$4.00SrtwqhFbkcldcdx

Shares in Nanosonics Screen As Undervalued

Business Strategy and Outlook

Nanosonics’ Trophon solution for high-level disinfection of ultrasound probes has garnered substantial market share, evidenced by penetration of over 75% in Australia and New Zealand and 40% in North America. We expect elevated growth over the next three years as Trophon continues to gain share in North America and launch in Japan, but high market penetration may be more challenging to achieve in developing economies, which may not be able to prioritize nuanced disinfection standards. Moreover, the device patent expires in 2025, leading to slower volume growth in the medium term.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of NAN so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center